144 research outputs found

    Semi-classical analysis of a random walk on a manifold

    Full text link
    We prove a sharp rate of convergence to stationarity for a natural random walk on a compact Riemannian manifold (M,g)(M,g). The proof includes a detailed study of the spectral theory of the associated operator.Comment: Published in at http://dx.doi.org/10.1214/09-AOP483 the Annals of Probability (http://www.imstat.org/aop/) by the Institute of Mathematical Statistics (http://www.imstat.org

    Gibbs/Metropolis algorithms on a convex polytope

    Get PDF
    This paper gives sharp rates of convergence for natural versions of the Metropolis algorithm for sampling from the uniform distribution on a convex polytope. The singular proposal distribution, based on a walk moving locally in one of a fixed, finite set of directions, needs some new tools. We get useful bounds on the spectrum and eigenfunctions using Nash and Weyl-type inequalities. The top eigenvalues of the Markov chain are closely related to the Neuman eigenvalues of the polytope for a novel Laplacian.Comment: 21 pages, 1 figur

    Spectral Analysis of hypoelliptic random walks

    Full text link
    We study the spectral theory of a reversible Markov chain associated to a hypoelliptic random walk on a manifold M. This random walk depends on a parameter h which is roughly the size of each step of the walk. We prove uniform bounds with respect to h on the rate of convergence to equilibrium, and the convergence when h goes to zero to the associated hypoelliptic diffusion

    Random walk on surfaces with hyperbolic cusps

    Get PDF
    We consider the operator associated to a random walk on finite volume surfaces with hyperbolic cusps. We study the spectral gap (upper and lower bound) associated to this operator and deduce some rate of convergence of the iterated kernel towards its stationary distribution.Comment: 28 page

    The effect of university–industry collaboration on the scientific impact of publications : the Canadian case, 1980–2005

    Get PDF
    Previous research on university-industry collaboration in Canada concluded, using mean impact factors as a proxy, that the scientific impact of such research is not inferior to that of university research. Using field-normalized impact factors and citation counts, this paper reexamines the Canadian case. It shows that, when impact factors are field-normalized, university-industry papers are published, on average, in journals with lower impact factors than papers originating from universities only. However, field-normalized citation values reveal the opposite: the average scientific impact of university-industry papers is significantly above that of both university-only papers and industry-only papers. Collaboration with industries is, thus far from detrimental to the scientific impact of university research and even increases it significantly

    Direct synthesis of mesoporous silica containing cobalt: A new strategy using a cobalt soap as a co-template

    Get PDF
    A novel approach to incorporate transition metals into porous structures is presented, which makes use of a cobalt soap in combination with the templating agent C16TMABr. An ordered mesoporous silica MCM-41 type material doped with Co is obtained after removal of the organic part by calcination. The a unit cell parameter of the cobalt containing mesoporous matrices is larger than that of pure MCM-41 and increases with the amount of cobalt present in the sample as well as the diameter of the pores. This is not observed when e.g. cobalt acetate is employed instead of the metal soap. The procedure presented establishes a new route for the incorporation of a transition metal into MCM-41 together with a tuning of the porous structure

    Effects of a multifaceted intervention on cardiovascular risk factors in high-risk hypertensive patients: the ESCAPE trial, a pragmatic cluster randomized trial in general practice

    Get PDF
    BACKGROUND: Several observational studies on hypertensive patients have shown a gap between therapeutic targets recommended in guidelines and those achieved in daily practice. The ESCAPE trial aimed to determine whether a multifaceted intervention focused on general practitioners (GPs), could increase significantly the proportion of hypertensive patients at high risk in primary prevention who achieved all their recommended therapeutic targets. METHODS: A pragmatic, cluster randomized trial involving 257 GPs randomized by region. The GPs in the intervention group had a one-day training session and were given an electronic blood pressure measurement device and a short recommendation leaflet. Along with usual follow-up, they focused one consultation on hypertension and other cardiovascular risk factors every six months for two years. They also received feedback at baseline and at one year on their patients’ clinical and biological parameters. Main outcome measures were change in the proportion of patients achieving all their therapeutic targets and each individual therapeutic target at two years, and quality of life. RESULTS: 1,832 high-risk hypertensive patients were included. After two years, the proportion of patients achieving all their therapeutic targets increased significantly in both groups, but significantly more in the intervention group: OR (odds-ratio) 1.89, (95% confidence interval (CI) 1.09 to 3.27, P = 0.02). Significantly more patients achieved their blood pressure targets in the intervention group than in the usual care group: OR 2.03 (95% CI 1.44 to 2.88, P < 0.0001). Systolic and diastolic blood pressures decreased significantly more in the intervention group than in the usual care group, by 4.8 mmHg and 1.9 mmHg, respectively (P < 0.0001 for both). There were no significant difference changes in physical and mental quality of life between groups. CONCLUSION: An easy-to-perform, multifaceted intervention targeting only GPs increased significantly the proportion of high-risk hypertensive patients in primary prevention achieving their recommended therapeutic targets. TRIAL REGISTRATION: This trial was registered with ClinicalTrials.gov, number NCT0034885
    • …
    corecore